Literature DB >> 6861442

Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration.

K E Pedersen, B D Christiansen, K Kjaer, N A Klitgaard, F Nielsen-Kudsk.   

Abstract

Verapamil increases plasma digoxin concentration by about 60% to 80%. To explore the clinical consequences of this interaction, we evaluated single-dose digoxin kinetics along with repeated measurements of intraerythrocytic sodium concentration in eight healthy subjects before and during verapamil coadministration. Verapamil reduced mean total body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg and prolonged digoxin biologic t1/2 from 33.5 +/- 2.4 to 41.4 +/- 2.3 hr. These kinetic changes were associated with a greater elevation of intraerythrocytic sodium concentration than controls. Verapamil had no effect on intraerythrocytic sodium content. In vitro experiments revealed no influence of verapamil on the number of glycoside receptors on human lymphocytes. Since intracellular sodium concentration has proved to correlate closely with clinical signs of digoxin toxicity, our indicate that verapamil is likely to increase the risk of digoxin-induced arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861442     DOI: 10.1038/clpt.1983.121

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Interaction between Ca2+ antagonists and digitalis.

Authors:  J N Lessem
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 4.  Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

Authors:  H O Klein; E Kaplinsky
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 6.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 7.  Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Authors:  Kunal S Taskar; Xinning Yang; Sibylle Neuhoff; Mitesh Patel; Kenta Yoshida; Mary F Paine; Kim L R Brouwer; Xiaoyan Chu; Yuichi Sugiyama; Jack Cook; Joseph W Polli; Imad Hanna; Yurong Lai; Maciej Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

8.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953

9.  Verapamil-induced changes in digoxin kinetics in cirrhosis.

Authors:  I Maragno; C Gianotti; P F Tropeano; V Rodighiero; R M Gaion; C Paleari; R Prandoni; L Menozzi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.